SCHEMBL3493749

SCHEMBL3493749

N#Cc1ccc2c(c1)C(=O)CC1(CCN(C(=O)c3c(N)sc4ncccc34)CC1)S2

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 2/20 0.32
CYP3A4 P08684 3/20 0.32
MAPK1 P28482 2/20 0.32
CYP2D6 P10635 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
CYP1A2 P05177 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
PKLR P30613 2/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
PDE4B Q07343 1/20 0.31
ELANE P08246 2/20 0.31
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
EPHX2 P34913 1/20 0.30
IKBKB O14920 1/20 0.30
CHUK O15111 1/20 0.30
LIMK1 P53667 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492877 0.87 ATM (0.33) ACACBACACAIKBKBCHUKLIMK1
SCHEMBL3492176 0.87 ACACB (0.37) SLC6A7CYP3A4MAPK1CYP2D6ALDH1A1
SCHEMBL3492172 0.87 ACACB (0.37) SLC6A7CYP3A4MAPK1CYP2D6ALDH1A1
SCHEMBL3494572 0.87 SMN1; SMN2 (0.33) MAPK1ALDH1A1ACACBACACAIKBKB
SCHEMBL3491551 0.85 ACACB (0.40) CYP3A4MAPK1CYP2D6ALDH1A1TSHR
SCHEMBL3491550 0.85 ACACB (0.40) CYP3A4MAPK1CYP2D6ALDH1A1TSHR
SCHEMBL3491729 0.85 USP2 (0.33) CYP3A4CYP2D6CYP1A2PDE4BACACA
SCHEMBL3493754 0.83 ACACB (0.49) ACACBACACA
SCHEMBL3493757 0.83 ACACB (0.49) ACACBACACA
SCHEMBL13340495 0.83 ACACB (0.37) CYP3A4MAPK1CYP2D6ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113418-A1 HETEROCYCLIC COMPOUND ACACA, ACAT1, CPT1B SLC6A7 2418/4885CYP3A4 2607/4885MAPK1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.